SEARCH LISTED COMPANY
ANY AUS OR NZ COMPANY
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
Level 8, 210 George Street, Sydney NSW 2000 GPO Box 3993 Sydney NSW 2001
Tel : 1300 737 760 (in Australia) +61 2 9290 9600 (International)delisted at entity's request under Listing Rule 17.11 | 01/04/2022 |
we understand WFM Investments Pty Ltd, a wholly-owned subsidiary of Wesfarmers, has acquired 100 per cent of the shares in API for the total consideration of $1.55 cash per share, which included a special dividend of 5 cents paid on 29 March 2022 | 01/04/2022 |
Wesfarmers Limited today announced the implementation of the Scheme of Arrangement under which WFM Investments Pty Ltd, a wholly-owned subsidiary of Wesfarmers, has acquired 100 per cent of the shares in Australian Pharmaceutical Industries Limited. | 31/03/2022 |
The company confirms that the scheme of arrangement, under which WFM Investments Pty Ltd, a wholly owned subsidiary of Wesfarmers Limited, is to acquire 100% of the shares in API that it does not already own, was implemented today. WFM Investments Pty Ltd has now acquired all the issued shares in API. The Special Dividend was paid on 29 March 2022 to API shareholders in respect of API shares held as at 7.00pm (Melbourne time) on Friday, 25 March 2022 and the balance of the Scheme consideration was paid today to all API shareholders in respect of API shares held as at 7.00pm (Melbourne time) on Tuesday, 29 March 2022. | 31/03/2022 |
The company releases a notification of cessation of securities. | 29/03/2022 |
The company releases a letter to its shareholders regarding the special dividend payment. The API Board s pleased to confirm the payment of the fully franked Special Dividend of 3.0c per API Share. | 29/03/2022 |
The securities of Australian Pharmaceutical Industries Limited will be suspended from quotation at the close of trading on Tuesday, 22 March 2022 under Listing Rule 17.2, following lodgement of the Federal Court of Australia orders with ASIC approving the scheme of arrangement by which WFM Investments Pty Ltd, a wholly owned subsidiary of Wesfarmers Limited, will acquire all of the issued shares in API. | 22/03/2022 |
API has today announced that in preparation for the release of its half year results, it will incur an asset impairment charge of $131 million. Notwithstanding this non-cash charge, the underlying business performance is strong, with a net profit after tax of $16.2 million, subject to final auditor review, for the six months ended 28 February 2014 (up from $12.6 million for the prior comparable period). | 17/04/2014 |
The suspension of trading in the securities of Australian Pharmaceutical Industries Limited (the "Company") will be lifted immediately, following the Company's announcement in relation to the carrying value of its assets. Security Code: API | 17/04/2014 |
The securities of Australian Pharmaceutical Industries Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement regarding the carrying value of its assets. Security Code: API | 16/04/2014 |
shares reinstated to quotation | 22/08/2006 |
company advises that the Australian Securities & Investments Commission (ASIC) had granted the company an extension to lodge its Final Accounts on Monday 21 August 2006 - the Australian Stock Exchange (ASX) has advised that API shares will recommence trading the day following the Final Accounts being lodged with ASIC and the ASX | 18/08/2006 |
appoints new CEO, releases preliminary final report and Results for Year Ended 30 April 2006 and also a FY06 Results Presentation - the company has lost $17m but can't explain how or where | 14/08/2006 |
company advises that on Monday 14 August 2006 it will be releasing its full-year financial results for the year ended 30 April 2006. There will be a teleconference briefing held at 1 p.m. on 14 August. The teleconference can be accessed by calling: Dial in # 1800 097 137 Confirmation Code 5065872 | 11/08/2006 |
company advises that the Australian Securities & Investments Commission has granted the company an extension to enable the company to lodge its financial results and report for financial year 2006 on or by 14 August 2006 | 28/07/2006 |
the company today advised that while it had made progress on resolving a number of the issues delaying the release of its financial results, there are still some outstanding items that require further attention | 21/07/2006 |
shares suspended from quotation pending release of an announcement | 14/07/2006 |
Purchases Sales
| DATE | DIRECTOR | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|
| 14/12/2020 | Jennifer MacDonald | 25,000 | $1.305 | $32,625.00 |
| 24/04/2020 | Mark Smith | 40,000 | $1.039 | $41,550.00 |
| 23/04/2020 | Jennifer MacDonald | 15,000 | $1.010 | $15,150.00 |
| 03/02/2020 | Mark Smith | 30,000 | $1.299 | $38,981.00 |
| 20/12/2019 | Mark Smith | 40,000 | $1.320 | $52,800.00 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Richard Vincent | Managing Director, CEO | 15/02/2017 |
| Peter Sanguinetti | General Counsel | 30/11/2007 |
| Anne Mustow | Company Secretary |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|
Date of first appointment, title may have changed.
